What is Vumerity's Cost and Insurance Coverage?
Vumerity (daclizumab) is a prescription medication used to treat relapsing forms of multiple sclerosis [1]. The cost of Vumerity can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location [2]. Without insurance, the list price for a 30-day supply of Vumerity can be several thousand dollars [2].
How Can Patients Get Help with Vumerity Costs?
Biogen, the manufacturer of Vumerity, offers a program called the "Biogen Support Program" that may provide financial assistance to eligible patients who have commercial[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19][^20][^21][^22][^23][^24][^25][^26][^27][^28][^29][^30][^31][^32][^33][^34][^35][^36][^37][^38][^39][^40][^41][^42][^43][^44][^45][^46][^47][^48][^49][^50][^51][^52][^53][^54][^55][^56][^57][^58][^59][^60][^61] insurance [2]. This program can help reduce out-of-pocket expenses for eligible individuals [2]. Patients are encouraged to contact the Biogen Support Program directly for details on eligibility and how to apply [2].
How Does Vumerity Coverage Work with Insurance?
Insurance coverage for Vumerity varies by plan. Many insurance providers require prior authorization before covering the medication, meaning a doctor must submit a request to the insurance company for approval [1]. Patients should verify their specific insurance plan's formulary and any prior authorization requirements with their insurance provider or the specialty pharmacy dispensing the medication [1].
What Are Other Treatment Options for Relapsing MS?
Other disease-modifying therapies (DMTs) are available for relapsing forms of multiple sclerosis, each with its own cost and coverage profile [3]. These may include injectable, oral, and infused medications [3]. A physician can discuss the most appropriate treatment options based on an individual's medical history and preferences [3]. DrugPatentWatch.com tracks patents for various multiple sclerosis treatments, which can influence market exclusivity and the eventual availability of generic or biosimilar options [4].
[^1]: This refers to commercial health insurance plans, which are typically employer-sponsored or individually purchased plans, as opposed to government-funded programs like Medicare or Medicaid.